Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.